We were interested to read the series of articles on the efficacy of intravenous immunoglobulin (IVIG) for the treatment of toxic epidermal necrolysis (TEN), published in the January issue of ARCHIVES. Most reports of trials of therapy in TEN are case series with no control group and so are difficult to interpret. The articles by Trent et al1 and Bachot et al2 address this by comparing actual mortality of IVIG-treated patients with mortality predicted by the SCORTEN prognostic scoring index.3
Collin B, Marshall T, Heagerty A. Scoring With SCORTEN. Arch Dermatol. 2003;139(9):1215. doi:10.1001/archderm.139.9.1215-a
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.